TARP dendritic cell vaccine / National Cancer Institute, PDS Biotech - LARVOL DELTA

Vaccine antigen-specific T cell responses persisted several years after initial vaccination in patients with prostate cancer who re-enrolled to a subsequent study involving multiepitope vaccination (SITC 2024) - P1, P2 | "Manufacturing of ME-TARP DC: Manufacturing of the multiepitope-TARP dendritic cell vaccine (ME-TARP DC) using peripheral blood monocytes from the patientsDownload figure Open in new tab Download powerpoint Abstract 597 Figure 3 Study enrollment. The patients who had been enrolled in the TARP Study were reviewed for eligibility of the ME-TARP Study. Of 41 patients from the TARP Study, 14 participants enrolled in the ME-TARP Study"

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD8 • IFNG

PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute (GlobeNewswire) - "PDS Biotechnology Corporation...announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP)....The worldwide, non-exclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034."

Licensing / partnership • Patent • Oncology